Author

Waqqas Afif

VEDOLIZUMAB THERAPEUTIC DRUG MONITORING AND REAL-WORLD OUTCOMES IN INFLAMMATORY BOWEL DISEASE
VEDOLIZUMAB THERAPEUTIC DRUG MONITORING AND REAL-WORLD OUTCOMES IN INFLAMMATORY BOWEL DISEASE

EFFICACY AND SAFETY OF USTEKINUMAB FOR ULCERATIVE COLITIS THROUGH 4 YEARS: FINAL RESULTS FROM THE UNIFI LONG-TERM EXTENSION
EFFICACY AND SAFETY OF USTEKINUMAB FOR ULCERATIVE COLITIS THROUGH 4 YEARS: FINAL RESULTS FROM THE UNIFI LONG-TERM EXTENSION

Waqqas Afif  et al.

VEDOLIZUMAB THERAPEUTIC DRUG MONITORING AND REAL-WORLD OUTCOMES IN INFLAMMATORY BOWEL DISEASE
VEDOLIZUMAB THERAPEUTIC DRUG MONITORING AND REAL-WORLD OUTCOMES IN INFLAMMATORY BOWEL DISEASE

Waqqas Afif

VEDOLIZUMAB THERAPEUTIC DRUG MONITORING AND REAL-WORLD OUTCOMES IN INFLAMMATORY BOWEL DISEASE
VEDOLIZUMAB THERAPEUTIC DRUG MONITORING AND REAL-WORLD OUTCOMES IN INFLAMMATORY BOWEL DISEASE

Waqqas Afif  et al.

EFFICACY AND SAFETY OF USTEKINUMAB FOR ULCERATIVE COLITIS THROUGH 4 YEARS: FINAL RESULTS FROM THE UNIFI LONG-TERM EXTENSION
EFFICACY AND SAFETY OF USTEKINUMAB FOR ULCERATIVE COLITIS THROUGH 4 YEARS: FINAL RESULTS FROM THE UNIFI LONG-TERM EXTENSION

TREATMENT DISCONTINUATION FOR BIOSIMILAR VERSUS ORIGINATOR IN INFLIXIMAB INITIATORS
TREATMENT DISCONTINUATION FOR BIOSIMILAR VERSUS ORIGINATOR IN INFLIXIMAB INITIATORS

Waqqas Afif  et al.

UCEIS IS ASSOCIATED WITH PRO2, PARTIAL MAYO AND SCCAI REMISSION IN UC: PRELIMINARY RESULTS FORM A PROSPECTIVE STUDY
UCEIS IS ASSOCIATED WITH PRO2, PARTIAL MAYO AND SCCAI REMISSION IN UC: PRELIMINARY RESULTS FORM A PROSPECTIVE STUDY

Waqqas Afif  et al.

PATIENT REPORTED OUTCOMES, PARTIAL MAYO SCORE AND SCCAI ARE EQUALLY ACCURATE IN PREDICTING MUCOSAL HEALING IN UC: PRELIMINARY RESULTS FORM A PROSPECTIVE STUDY
PATIENT REPORTED OUTCOMES, PARTIAL MAYO SCORE AND SCCAI ARE EQUALLY ACCURATE IN PREDICTING MUCOSAL HEALING IN UC: PRELIMINARY RESULTS FORM A PROSPECTIVE STUDY

Waqqas Afif  et al.

ACCURACY OF PANMAYO ENDOSCOPIC SCORE IN PREDICTING LONG-TERM DISEASE OUTCOMES IN ULCERATIVE COLITIS– A PROMISING SCORING SYSTEM
ACCURACY OF PANMAYO ENDOSCOPIC SCORE IN PREDICTING LONG-TERM DISEASE OUTCOMES IN ULCERATIVE COLITIS– A PROMISING SCORING SYSTEM

Waqqas Afif  et al.

CORTICOSTEROID-SPARING EFFECTS OF USTEKINUMAB THERAPY FOR ULCERATIVE COLITIS THROUGH 4 YEARS: UNIFI LONG-TERM EXTENSION
CORTICOSTEROID-SPARING EFFECTS OF USTEKINUMAB THERAPY FOR ULCERATIVE COLITIS THROUGH 4 YEARS: UNIFI LONG-TERM EXTENSION

Waqqas Afif  et al.

PHARMACOKINETICS AND IMMUNOGENICITY OF MAINTENANCE THERAPY WITH USTEKINUMAB: 2-YEAR RESULTS FROM THE UNIFI LONG-TERM EXTENSION STUDY
PHARMACOKINETICS AND IMMUNOGENICITY OF MAINTENANCE THERAPY WITH USTEKINUMAB: 2-YEAR RESULTS FROM THE UNIFI LONG-TERM EXTENSION STUDY

Waqqas Afif  et al.

EFFICACY OF USTEKINUMAB FOR ULCERATIVE COLITIS IN PATIENTS THROUGH 3 YEARS: UNIFI LONG-TERM EXTENSION
EFFICACY OF USTEKINUMAB FOR ULCERATIVE COLITIS IN PATIENTS THROUGH 3 YEARS: UNIFI LONG-TERM EXTENSION

Waqqas Afif  et al.

EFFECTIVENESS OF THIRD-CLASS BIOLOGIC TREATMENT IN CROHN´S DISEASE: A MULTI-CENTER RETROSPECTIVE COHORT STUDY
EFFECTIVENESS OF THIRD-CLASS BIOLOGIC TREATMENT IN CROHN´S DISEASE: A MULTI-CENTER RETROSPECTIVE COHORT STUDY

Waqqas Afif  et al.

Item 1 - 13 / 13
1